Loss of p53 and overexpression of EphA2 predict poor prognosis for ovarian cancer patients.
Meade-Tollin
Linda
L
Department of Surgery, Arizona Cancer Center, University of Arizona College of Medicine, 1501 North Campbell Avenue, Tucson, AZ 85724, USA. glato1@mindspring.com
Martinez
Jesse D
JD
D014408:Biomarkers, Tumor; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D016158:Genes, p53 / Q000235:genetics*; D006801:Humans; D010051:Ovarian Neoplasms / Q000235:genetics*; D011379:Prognosis; D036104:Receptor, EphA2 / Q000096:biosynthesis*; D015854:Up-Regulation
D014408:Biomarkers, Tumor; D036104:Receptor, EphA2